Key Findings
The U.S. Food and Drug Administration (FDA) is set to announce a crucial decision regarding NASP (nanocapsulated sirolimus + pegadricase), a candidate drug for refractory gout, on June 27, 2026. This decision could bring new hope to gout patients with limited current treatment options and represents a significant milestone in the clinical application of nanomedicine technology.
Technical and Clinical Details
NASP is an innovative intravenous infusion formulation comprising two key components. One component is nanocapsulated sirolimus, an immunosuppressant, which is expected to mitigate the formation of anti-drug antibodies (ADAs) against the second component, pegadricase. Pegadricase is an enzyme therapy used to treat hyperuricemia-related gout, effectively breaking down uric acid in the body and lowering serum uric acid levels.
The drug was evaluated for both efficacy and safety in high and low doses during Phase 3 clinical trials, ‘DISSOLVE I’ and ‘DISSOLVE II.’ These trials enrolled patients with severe gout who had shown inadequate response to conventional therapies. The studies assessed NASP’s ability to reduce serum uric acid to target levels and decrease the frequency of gout flares. The nanocapsulation technology aims to improve the pharmacokinetics of sirolimus and suppress ADA reactions, thereby sustaining the long-term effectiveness of pegadricase.
Background and Industry Context
Gout is an inflammatory arthritis caused by hyperuricemia, which, if severe, can lead to joint damage and impaired kidney function. Patients with ‘refractory gout’ who do not respond to existing uric acid-lowering drugs have particularly limited treatment options, leading to a significant reduction in their quality of life. While pegadricase is approved for refractory gout, some patients develop ADAs, which can diminish treatment efficacy. The development of NASP represents a strategic approach to overcome this ADA issue and extend the effectiveness of pegadricase to a broader patient population.
Strategic Significance and Outlook
The FDA’s decision on NASP could profoundly impact the treatment landscape for refractory gout. If approved, NASP would offer a new therapeutic option for patients resistant to conventional treatments, enabling more sustained and effective uric acid control. This development demonstrates the ability of nanocapsulation technology to manage drug immunogenicity and optimize therapeutic outcomes, with potential applications for other immunogenic drugs. The market introduction of NASP is expected to improve the quality of life for gout patients and contribute to healthcare cost reductions.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments